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Background: The incidence of malignant melanoma has continually increased during the
past few decades, however, certain reports suggest a recent change in trends. The aim of
our study was to examine the epidemiology of melanoma in Hungary.
Methods: This nationwide, retrospective, longitudinal study included melanoma patients
diagnosed between 1 January 2009 and 31 December 2019 using the databases of the
National Health Insurance Fund (NHIF) and Central Statistical Office (CSO) of Hungary.
Age-standardized incidence and cause-specific mortality rates were calculated.
Results: We identified 2,426 and 2,414 new melanoma cases in 2011 and in 2019. Age-
standardized incidence rates were higher in males and varied between 28.28 and 34.57/
100,000 person-years (PYs), and between 22.63 and 26.72/100,000 PYs in females. We
found 16.14 and 18.82% increases in male and female incidence rates from 2011 to 2015
(p=0.067 and p<0.001, respectively), and 12.77 and 11.35% decreases from 2015 to 2019
(p=0.062 and p=0.004, respectively). The change of incidence trends (2011–2015 vs. 2015–
2019) was significant in females (p=0.002) and in the total melanoma population (p=0.011),February 2021 | Volume 10 | Article 6124591
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Frontiers in Oncology | www.frontiersin.orgbut not in the male population (p=0.063). A 16.55% (95% CI: −27.07 to −4.59; p=0.013)
decrease in mortality rates was found in the overall melanoma population.
Conclusions: We observed a significant trend change in melanoma incidence in the
female and total melanoma population, and a significant decrease in mortality in the total
melanoma population. These changes may be attributed to intensive melanoma
awareness campaigns as well as to the increase in screening and access to modern
therapies.Keywords: melanoma, incidence, mortality, trend change, HungaryINTRODUCTION
The incidence of malignant melanoma has shown a continuous
increase worldwide among light-skinned populations during the
past few decades (1–5). In Europe, the estimated age-
standardized rates (ASRs per 100,000 person-years, PYs) of
melanoma incidence increased from 11.4 in males and 11.0 in
females in 2012 to 15.8 and 14.6 in 2018, respectively (6, 7).
Although incidence rates are still increasing in most European
countries, certain high-risk countries, including Australia,
Scandinavia, the United Kingdom and the United States have
reported a levelling off or stabilization in melanoma incidence
rates mainly in younger age groups starting from the late 1990s
in contrast to the dramatic increase during the preceding years
(1, 3, 8–11). Due to the significant burden of the disease, several
countries have implemented educational programs and
prevention campaigns, the long-term impact of which are yet
to be seen during the upcoming years (12, 13).
Parallel to the overall increasing incidence, the mortality of
melanoma has also been reported to increase in the past few
decades (4, 5, 14, 15). However, the increase in mortality also
seems to have decelerated or halted in certain regions, and several
recent reports even suggest a slight decrease in younger age
groups, which may be attributed to the introduction of modern
therapies as well as to screening, improved early recognition and
the implementation of awareness programs (9, 16–20).
Based on the estimations by Ferlay et al., Hungary was in the
middle rank of the spectrum ofmelanoma incidence andmortality
both in 2012 and 2018 (6, 7). It should be noted that the incidence
rates for Hungary were estimated based on mortality-to-incidence
(M/I) ratios from neighboring countries and thus cannot be
considered an accurate and appropriate basis for evaluation.
Therefore, our current population-based analysis aimed to
examine the incidence and mortality of melanoma in Hungary
between 2011 and 2019, and to compare data with international
findings from the same period.MATERIALS AND METHODS
Study Design
Our nationwide, retrospective, longitudinal study was conducted
using the databases of the National Health Insurance Fund of
Hungary (NHIF) and Central Statistical Office (CSO). The NHIF2
database is a comprehensive database covering close to 100% of
the Hungarian population which contains prescription claims
data from all reimbursed medicinal products as well as ICD-10
code information about all in- and out-patient visits. The CSO
database collects cause-specific mortality data on all deceased
Hungarian citizens on a yearly basis.
The present analysis included patients with malignant
melanoma (ICD-10 C43) who were diagnosed between 1
January 2009 and 31 December 2019 and were ≥20 years of age
at the time of diagnosis. To avoid the potential miscoding of
melanoma, we included patients with a minimum of two
occurrences of the ICD-10 code C43. Only one occurrence of
C43 was also accepted if the patient died within 60 days after the
first ICD-10 code. The 2-year-long period between 2009 and 2010
was considered a reference period to detect newly diagnosed
melanoma patients from 2011. Hungarian population sizes for
incidence and prevalence calculations by age and sex, as well as
dates and numbers of cause-specific mortality among melanoma
patients were obtained from the Hungarian CSO. All-cause
mortality data were retrieved from the NHIF database for the
cumulative prevalent melanoma population. Thus, we are able to
calculate all-cause mortality as well as cause-specific mortality data
for the melanoma population on a yearly basis.
For the calculation of incidence rates, annual numbers of
patients newly diagnosed with melanoma are given as crude
numbers (n), new cases were counted for each calendar year,
(between 1 January and 31 December). Annual incidence rates are
expressed as standardized rates (per 100,000 PYs). In addition, we
also calculated annual cumulative incidence as percentages (%) of
the total population at risk. Total population at risk was
determined by subtracting the number of prevalent melanoma
cases known on 1 January of a given year from the total population
of the same year based on annual mid-year population estimates
from the CSO.
For prevalence calculations, the number of melanoma patients
was determined using the annual number of melanoma patients
who were alive on 1 January of the given year. Patients newly
diagnosed in the given year were also included in the annual
prevalence. Annual prevalence was expressed as crude numbers
(n), in addition, we also calculated prevalence rates as percentages
(%) of the total population based on annual mid-year population
estimates from the CSO (21). Age-standardized prevalence per
100,000 PYs were also calculated by sex using the cohort weights
from European Standard Population (ESP) 2013.February 2021 | Volume 10 | Article 612459
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data from the CSO database. We considered the number of
patients who died of melanoma between 1 January and 31
December of a given year as the number of melanoma cause-
specific deaths. Melanoma-specific mortality was expressed as
crude numbers (n) and standardized rates per 100,000 PYs. We
used standardized incidence and cause-specific mortality rates to
evaluate trends in incidence and mortality over time. Total
changes and annual changes between 2011–2019, 2011–2015
and 2015–2019 were presented as percentages (%).
To allow for direct comparisons with recent and earlier
publications, incidence and mortality data were adjusted for
age using both ESP 1976 and 2013 for standardization. Where
crude numbers of any parameter were recorded below 10, we
indicated “<10” as the NHIF data protection rule does not allow
the presentation of case numbers below 10 in a stratum. In these
cases, calculations were run on the exact crude numbers. The
study protocol was approved by the National Ethical Board for
Health Research (IV2581-2/2020/EKU).Statistical Analysis
Regression models were used to estimate annual trends with 95%
confidence intervals (95% CI). As data were not independent, a
block-based bootstrap method was used for time series with a
fixed block size of 2. Hungarian population sizes were calculated
based on mid-year population sizes published by the Hungarian
CSO. The size of the at-risk population was determined based on
the difference between mid-year population sizes and the number
of previously diagnosed melanoma patients on 1 January in a
given year. Poisson regression was used for the calculations of
annual change of incidence and mortality. In the 2011 to 2019
period the outcome was the number of patients, the offset was the
log of the number of patients at risk or the mid-year population,
the explanatory variables were the year. When comparing the
periods 2011–2015 and 2015–2019, the outcome was the number
of patients, the offset was the log of the number of patients at risk
or the mid-year population, the two explanatory variables were the
number of years since 2011 and the number of years since 2015.
All calculations were performed with R version 3.6.1 (05/07/2019)
with package boot version 1.3-20.RESULTS
Crude Numbers
We identified 2,426 and 2,414 new melanoma cases in 2011 and
2019 from the NHIF database, respectively, corresponding to
0.02–0.03% of the total Hungarian population at risk (Table 1)
The proportion of male patients varied from 49.51 to 45.64%
between 2011 and 2019. The mean age at diagnosis was 61.84
years in men (SD ± 15.18) and 59.80 years in women (SD ±
16.80) in 2011, and 63.45 (SD ± 15.08) and 58.91 years (SD ±
16.17) in 2019 (Figure 1, Supplementary Table 1). The total
number of identified melanoma patients increased from 15,388
to 28,660 during the study period, with female dominance (56.99
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Liszkay et al. Changing Melanoma Epidemiology in HungaryThe annual number of melanoma patients who died from any
cause increased from 707 (2011) to 1,183 (2019), while
melanoma cause-specific mortality decreased from 365 to 318
per year during the study period. The mean age at the time of all-
cause death increased from 69.77 (SD ± 13.14) to 76.37 (SD ±
12.26) years between 2011 and 2019, and was higher among
females during the whole study period (70.42–77.50 years vs.
69.33–74.65 years in males) (Figure 1, Supplementary Table 1)
Incidence
Age-standardized incidence rates (ESP 2013) were higher in males
during the whole study period, with the lowest rate found in 2012
(28.28/100,000 PYs; 95% CI: 26.59–29.97) and highest in 2015
(34.57/100,000 PYs, 95% CI: 32.73–36.42) (Figure 2,
Supplementary Table 2). We found a 16.14% increase in
incidence rates between 2011 and 2015 in males (mean annual
change: 3.81 (95% CI: −0.29–11.13); p=0.067) (Supplementary
Table 3). Conversely, a 12.77% decrease was seen during the
2015–2019 period (mean annual change: −3.36%; 95% CI: −5.50–
0.92; p=0.062). Age-standardized incidence rates in females
increased by 18.82% from 22.63 to 26.72/100,000 PYs in the
2011–2015 period (95% CI: 10.5–42.58; p<0.001), then
decreased by 11.35% to 22.72/100,000 PYs (95% CI: −15.35 to
−3.05; p=0.004) by 2019. Adjusted incidence rates for the total
melanoma population increased by 3.76% yearly (95% CI: 1.28–
8.87; p=0.009) in the first, and decreased by 3.00% (95% CI: −4.18
to −0.63; p=0.035) in the second period (Supplementary Table 3).
The analysis of trends in the two study periods (2015–2019 vs.
2011–2015) revealed significant differences in females as well as in
the total melanoma population (change in females: −7.06%; 95%
CI: −11.77 to −3.54; p=0.002; change in total population: −6.51%;
95% CI: −11.65 to −2.23; p= 0.011), and a non-significant trend
change in the male melanoma population (change: −6.91%; 95%
CI: −14.23–0.69; p=0.063).
Mortality
Age-standardized, cause-specific mortality rates (ESP 2013) of
melanoma varied between 5.98 (95% CI: 5.18–6.78) and 4.73
(95% CI: 4.03–5.42) per 100,000 PYs in men, and between 2.33
(95% CI: 1.94–2.73) and 3.20 (95% CI: 2.73–3.66) in women in the
2011–2018 period (Figure 3, Supplementary Table 4). There was
no significant change in age-standardized cause-specific mortality
rates in male patients from 2011 to 2018 (change: −11.86%; 95% CI:
31.4–17.59; p=0.233) or in the female melanoma population
(change: −19.1%; 95% CI: −44.00–8.69; p=0.094). However, a
significant decrease by 16.55% (95% CI: −27.07 to −4.59;
p=0.013) was found during the 2011–2018 period in the overall
melanoma population (Supplementary Table 5). We did not find
any significant change in trends between the 2011–2015 and 2015–
2018 periods in any of the sexes, nor in the total melanoma
population (p=0.312, p=0.163, p=0.779 for the female, male, and
overall populations, respectively) (Supplementary Table 5).
Incidence and Mortality Compared to
Other European Countries
In our current study, the age-standardized incidence of
melanoma per 100,000 PYs was 20.41 in men (95% CI: 19.25–Frontiers in Oncology | www.frontiersin.org 421.58), while age-standardized mortality was 3.01 (95% CI: 2.57–
3.45) in 2018 (using ESP 1976 for standardization). These results
are different from the data reported by Ferlay et al. for Hungary
from the same year, with estimated ASRs of 14.0 for incidence
and 2.9 for mortality (Figure 4). There was also a considerable
difference between our results based on the NHIF database and
the publication by Ferlay et al. among women: we found an
incidence rate of 20.13 (95% CI: 19.06–21.21) and a mortality
rate of 1.66 (95% CI: 1.38–1.93) in 2018 (Supplementary Table
6), while those reported by Ferlay et al. were 13.20 and 2.10,
respectively. We also compared the age standardized incidence
rates of European countries On Supplementary Figure 1 for
both sexes using the Ferlay reports from 2012 and 2018 (6, 7).DISCUSSION
The main findings of our nationwide, long-term retrospective
study can be summarized as follows:
1. We found strong statistical evidence for a change in the trend
of age-standardized melanoma incidence starting from 2015.
2. Age-standardized cause-specific melanoma mortality rates
decreased from 2011 to 2018 in the male, female, and overall
melanoma populations, with a statistically significant decrease
of 16.55% observed in the total population. The mean age of
melanoma patients at the time of death increased by
approximately 6–7 years during the study period in both sexes.Incidence
Melanoma has been reported as one of the most common cancer
types among light-skinned people in recent years (7, 22–24).
Several countries have reported a continuous increase in
melanoma incidence during recent decades until the mid-
2010s (25–27). The reasons for this increasing trend are
multifactorial. Greater public awareness and increased
detection as well as the development and broader use of high-
accuracy diagnostic tools may explain some of the increase in
incidence rates (25, 28, 29). However, a recent U.S. study
reported increasing rates even in populations with limited
access to quality healthcare, suggesting that at least some of the
rise is due to a real increase in incidence (26). Increased exposure
to UV radiation may be responsible for the largest proportion of
the increase in incidence, which is in line with the fact that the
most affected regions are circumpolar areas (30–32). Sun-seeking
behaviour and the increasing use of tanning beds also contribute
to the increasing incidence of melanoma, especially in younger
age groups (33, 34). Furthermore, as melanoma incidence
increases with age and the highest rates can be found among
people over 80 years, an ageing population is also an important
driver for the increase (11).
Our study reports age-standardized incidence rates from the
very recent years. Since all melanoma cases registered in 2019
were already available in the NHIF database at the time of our
manuscript submission, this study is among the very few
reporting data on melanoma incidence from the second half ofFebruary 2021 | Volume 10 | Article 612459
Liszkay et al. Changing Melanoma Epidemiology in HungaryFIGURE 2 | Age-standardized incidence rates (ESP 2013) of melanoma (C43) by sex in Hungary between 2011 and 2019 (per 100,000 person-years; dotted lines
represent 95% CI). CI, confidence interval; ESP, European Standard Population.FIGURE 1 | Mean age of melanoma patients at diagnosis and at the time of death (all-cause mortality).Frontiers in Oncology | www.frontiersin.org February 2021 | Volume 10 | Article 6124595
Liszkay et al. Changing Melanoma Epidemiology in Hungarythe 2010s. Our findings based on the NHIF database are
supported by data from the Hungarian National Cancer
Registry, despite differences in data collection methods: the
difference in the annual number of newly diagnosed melanoma
patients in the two data sources was below 5% (Hungarian
National Cancer Registry) (35).
We found significant changes in melanoma incidence trends
starting from 2015. Between 2011 and 2015, the mean annual
increase in incidence was significant, 3.76% in the overall
melanoma population. In contrast, relevant and statistically
significant changes in trends were observed between 2015 and
2019, with a mean annual decrease of 3.00%. The change between
the 2015–2019 and 2011–2015 periods was also significant.
Primary prevention has been in the focus of the Hungarian
Society of Dermatology for decades. Hungary joined the
Euromelanoma skin cancer prevention and education alliance
formally in 2009 and enter the international scientific
collaborations (36–38). Before this time, the Hungarian Society
of Dermatology successfully organized and offered skin cancer
screenings countrywide with public awareness campaign with the
aims to stress the importance of sun protection and early
recognition of suspicious malignant lesions. By joining to the
Euromelanoma campaign, the Hungarian screening campaign
reached even wider population, by 2013 15.000 people asked
dermatological examination (39). Local implementation of the
Euromelanoma program is based on local observations to increase
its penetration into the lay community. As such, the health
consciousness of the subgroup of people seeking dermatological
screening under the umbrella of Euromelanoma at the University
of Szeged was evaluated by a detailed questionnaire. They foundFrontiers in Oncology | www.frontiersin.org 6that these patients were health-conscious regarding cardiovascular
diseases and attend cancer screenings on recall. However, their
knowledge about melanoma is insufficient, eg. most of them
perform skin self-examination, but they did not know what to
check, lesion was detected mostly by the patients themselves, but it
took more than one year to consult a doctor. Our study confirmed
that patients’ attitude toward melanoma is an important factor
influencing early detection therefore which should be introduced
into the routine medical care (40). In parallel with the above
mentioned efforts made by the dermatologist community in
Hungary, scientific reports evaluated the epidemiology of
melanoma which showed gradual transformation of the body
of incident melanoma cases over time. The National Institute of
Oncology analysed cutaneous malignant melanoma cases over 10
years, between 1998 and 2008. Although the number of cutaneous
melanomas showed an 153% increased between 1998 and in 2008,
the mean of Breslow numbers decreased significantly from 2.2mm
to 1.6 mm (p = 0.0002). Clark numbers were also decreasing trend,
although the difference was not significant (p = 0.08) (41). Another
report investigated the newly recognized cutaneous melanoma in
the University of Debrecen hospital-based registry in North-East
Hungary from 2000 to 2014. A total of 1509 cutaneous invasive
melanomas of 1464 patients were included in the study which
showed a moderate but significant increase in incidence [average
annual percentage change: 3.04 (0.07; 6.11); P = 0.045], with a
breakpoint in 2007. From 2001 to 2007, the trend was increasing
[APC: 9.84 (3.52; 16.55); P=0.006], but it stalled from 2007 [APC:
−2.45 (−5.99; 1.23); P = 0.164]. They found that the increase in the
incidence of cutaneous melanoma in the region from 2000 to 2008
was because of an increase in the number of diagnosed thinFIGURE 3 | Age-standardized mortality rates (standard: ESP 2013) of melanoma patients by sex in Hungary between 2011 and 2018 (per 100,000 person-years;
dotted lines represent the 95% CI). CI, confidence interval; ESP, European Standard Population.February 2021 | Volume 10 | Article 612459
Liszkay et al. Changing Melanoma Epidemiology in Hungarytumors (42). Based on the Hungarian National Meteorology
Service database, the change in annual amounts of biologically
effective UV radiation is significantly increasing from 1995 to 2010
period, where is a 2 years peak in 2010-2011 followed by a relevant
and significant decrease (43).
The incidence rates found in our study are comparable to data
from the Cancer Research UK database, with the same peaks
observed in 2015 in men and 2016 in women, respectively (11).
Although the majority of recent studies still report an increase in
melanoma incidence (4, 5), the changes in incidence trends
observed in the current analysis are not unprecedented. A
comprehensive analysis by Erdmann et al. examined global
patterns and trends in melanoma incidence in 39 countries
between 1953 and 2008, and found a stabilization of incidence
rates in the early 2000s in the white populations of Australia,
New Zealand, and North America, Israel, Iceland, and Norway,
with signs of a declining trend mainly in younger generations
(25–44 years) (1). Accordingly, a U.S. analysis found statistically
significant decreases in melanoma incidence for adolescents and
young adults between 2006 and 2015 (44). Furthermore,
although Ferlay’s articles on cancer incidence did not discuss
changes in incidence between 2012 and 2018, they reported
lower male and/or female melanoma incidence rates in 2018
compared to 2012 for certain European countries such as Latvia,
Ireland, Croatia, Spain and Switzerland, using similarFrontiers in Oncology | www.frontiersin.org 7standardization. By comparing the 2018 and 2012 Ferlay
reports on estimated melanoma incidence (Supplementary
Figure 1), we could find increase at most countries, however
there are some ones showing decrease during this period, like
Slovakia, where incidence rate decreased from 14.9 onto 13.6 per
100.000 person at males and 12.1 onto 10.5 at females. We could
demonstrate decrease in incidence in Iceland and Montenegro at
both sex, in Croatia. There were no relevant changes in Czech,
Slovakia, Spain, Portugal, Poland, Bulgaria, Russia, Romania and
Albania, where the difference between two study years are less
relevant than in other countries where the incidence increased
significantly, like Belgium, Netherland and Norway (6, 7).
The change in incidence trends may be explained by the
spread of melanoma awareness campaigns which are aimed at
drawing attention to the role of UV radiation as a modifiable
environmental factor in the development of melanoma.
Australia, one of the most affected countries, has conducted a
number of successful educational and awareness campaigns
starting from the 1980s including the Healthy Text study and
the SunSmart skin cancer prevention program (13, 45, 46). The
Euromelanoma Skin Cancer Prevention Campaign founded in
1999 is now active in 33 European countries with public
awareness campaigns and melanoma screening days, scientific
publications and special events (12, 47–49). A decreasing trend
in the overall use of tanning beds has been reported by a numberFIGURE 4 | Age-standardized incidence and mortality rates per 100,000 person-years among male melanoma (C43) patients in European countries and Hungary
based on the NHIF survey in 2018 (ESP 1976). ESP, European Standard Population. Description, A dot in the graph shows age-standardized incidence and mortality
rates together for a country. The Y axis represents the standardized mortality rate per 100,000 population, while the X axis represents the standardized incidence
rate per 100,000 population. (EU-28, 28 European member states; RAMM, name of current Hungarian study; Hungary Ferlay, reference numbers of Hungary from
Ferlay publication).February 2021 | Volume 10 | Article 612459
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awareness campaigns (50, 51). The estimations by Guy et al.
suggest that a comprehensive skin cancer prevention program
could help achieve a plateau in incidence and prevent 20% of
melanoma cases between 2020 and 2030 among white males and
females in the U.S. (3). Based on these publications and results
from our study, a change in melanoma incidence can be expected
in more and more countries in the upcoming decades.
Mortality
Age-standardized melanoma mortality rates in the male and
female populations were similar to the European average (6, 7).
In addition, our study found a 16.55% (p=0.013) decrease in
mortality in the total melanoma population from 2011 to 2018,
although the change was not significant in males and
females separately.
Decreasing trends in melanoma mortality have been reported
by a number of studies, which can be attributed to earlier detection
and the development of diagnostic modalities as well as the
availability of life-prolonging modern therapies (18, 52). The
real breakthrough in melanoma survival was brought about by
the development of molecular targeted and immune checkpoint
inhibitor therapies which have provided dramatic survival benefit
for melanoma patients and are considered as standard-of-care
treatment regimens for patients with metastatic melanoma (53,
54). As a result, improved survival has been demonstrated by an
increasing number of real-world studies (17, 20, 55). However,
certain countries still report increasing incidence and mortality
rates, highlighting that there is still room for improvement in
melanoma prevention and management (4, 5).
Incidence and Mortality Rate of Hungary in
Accordance of European Countries
We found higher incidence rate of melanoma in Hungary for
2018 as it was presented before in Ferlay publication (7). The
base of main difference is due to the method how Ferlay
estimated the incidence data for those countries, which did not
report any incidence data for melanoma (and other cancer
types). Hence, Ferlay used the mortality to incidence rate ratios
of neighbourhood countries and applied to the reported
mortality data of Hungary. Therefore, measured incidence of
melanoma in Hungary could differ from previous estimations.
On the other hand, we did not find relevant difference between
Ferlay and our data in case of mortality rates, as we used the same
source, the Hungarian Centre of Statistic Office. Nevertheless, the
presentation of incidence and mortality rates on Figure 4
demonstrate that melanoma burden in Hungary is close to
Europe and EU 28 member states’ average as well as to
Slovenia, Slovakia and Czech, which neighbourhood countries
are on the same latitude than Hungary.
Our study has certain strengths and limitations. The
nationwide nature of the NHIF database allowed for the
inclusion of all melanoma patients diagnosed between 2011
and 2019 in Hungary and thus provides a robust basis for our
study. However, the database does not contain any information
on patient characteristics, laboratory data, vital signs, or baseline
prognostic features.Frontiers in Oncology | www.frontiersin.org 8CONCLUSION
Our study is the first nationwide analysis describing the
incidence and mortality of melanoma in Hungary during the
very recent years. Incidence rates were slightly higher compared
to previous reports, while mortality rates were similar. We
observed significant trend changes in melanoma incidence and
mortality starting from 2015, which may be attributed to
intensive melanoma awareness campaigns as well as to the
increase in screening and access to modern therapies.
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Syntesia Medical Communications for medical writing support.SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fonc.2020.
612459/full#supplementary-material
Supplementary Figure 1 | Melanoma incidence rate of European countries in
2012 and 2018 by sex based on Ferlay reports (6, 7).February 2021 | Volume 10 | Article 612459
Liszkay et al. Changing Melanoma Epidemiology in HungaryREFERENCES
1. Erdmann F, Lortet-Tieulent J, Schüz J, Zeeb H, Greinert R, Breitbart EW, et al.
International Trends in the Incidence of Malignant Melanoma 1953-2008–are
Recent Generations at Higher or Lower Risk? Int J Cancer (2013) 132(2):385–
400. doi: 10.1002/ijc.27616
2. ArnoldM, Holterhues C, Hollestein LM, Coebergh JWW, Nijsten T, Pukkala E,
et al. Trends in incidence andpredictions of cutaneousmelanoma across Europe
up to 2015. J Eur Acad Dermatol Venereol (2014) 28(9):1170–8. doi: 10.1111/
jdv.12236
3. Guy GPJr, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson
LC, et al. Vital Signs: Melanoma Incidence and Mortality Trends and
Projections - United States, 1982-2030. MMWR Morb Mortal Wkly Rep
(2015) 64(21):591–6.
4. Sacchetto L, Zanetti R, Comber H, Bouchardy C, Brewster DH, Broganelli P,
et al. Trends in Incidence of Thick, Thin and in Situ Melanoma in Europe. Eur
J Cancer (2018) 92:108–18. doi: 10.1016/j.ejca.2017.12.024
5. Garbe C, Keim U, Eigentler TK, Amaral T, Katalinic A, Holleczek B, et al.
Time Trends in Incidence and Mortality of Cutaneous Melanoma in
Germany. J Eur Acad Dermatol Venereol (2019) 33(7):1272–80. doi:
10.1111/jdv.15322
6. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW,
Comber H, et al. Cancer Incidence and Mortality Patterns in Europe:
Estimates for 40 Countries in 2012. Eur J Cancer (2013) 49(6):1374–403.
doi: 10.1016/j.ejca.2012.12.027
7. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al.
Cancer Incidence and Mortality Patterns in Europe: Estimates for 40
Countries and 25 Major Cancers in 2018. Eur J Cancer (2018) 103:356–87.
doi: 10.1016/j.ejca.2018.07.005
8. Hall HI, Miller DR, Rogers JD, Bewerse B. Update on the Incidence and
Mortality From Melanoma in the United States. J Am Acad Dermatol (1999)
40(1):35–42. doi: 10.1016/S0190-9622(99)70562-1
9. de Vries E, Bray FI, Coebergh JWW, Parkin DM. Changing Epidemiology of
Malignant Cutaneous Melanoma in Europe 1953-1997: Rising Trends in
Incidence and Mortality but Recent Stabilizations in Western Europe and
Decreases in Scandinavia. Int J Cancer (2003) 107(1):119–26. doi: 10.1002/
ijc.11360
10. Australian Institute of Health and Welfare. Skin cancer in Australia. Cat. no.
CAN 96 (2016). Canberra, Australia: AIHW. Available at: https://www.aihw.
gov.au/getmedia/0368fb8b-10ef-4631-aa14-cb6d55043e4b/18197.pdf.aspx?
inline=true (Accessed 29 May 2020).
11. Cancer Research UK.Melanoma skin cancer incidence trends over time (2020).
Available at: https://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/melanoma-skin-cancer/incidence#heading-
Two (Accessed 26 May 2020).
12. van der Leest RJT, de Vries E, Bulliard J-L, Paoli J, Peris K, Stratigos AJ, et al.
The Euromelanoma Skin Cancer Prevention Campaign in Europe:
Characteristics and Results of 2009 and 2010. J Eur Acad Dermatol
Venereol (2011) 25(12):1455–65. doi: 10.1111/j.1468-3083.2011.04228.x
13. Tabbakh T, Volkov A, Wakefield M, Dobbinson S. Implementation of the
SunSmart Program and Population Sun Protection Behaviour in Melbourne,
Australia: Results From Cross-Sectional Summer Surveys From 1987 to 2017.
PloS Med (2019) 16(10):e1002932. doi: 10.1371/journal.pmed.1002932
14. Whiteman DC, Bray CA, Siskind V, Green AC, Hole DJ, Macke RM. Changes
in the Incidence of Cutaneous Melanoma in the West of Scotland and
Queensland, Australia: Hope for Health Promotion? Eur J Cancer Prev
(2008) 17(3):243–50. doi: 10.1097/CEJ.0b013e3282b6fe3f
15. Sneyd MJ, Cox B. A Comparison of Trends in Melanoma Mortality in New
Zealand and Australia: The Two Countries With the Highest Melanoma
Incidence and Mortality in the World. BMC Cancer (2013) 13:372. doi:
10.1186/1471-2407-13-372
16. Garbe C, Leiter U. Melanoma Epidemiology and Trends. Clin Dermatol
(2009) 27(1):3–9. doi: 10.1016/j.clindermatol.2008.09.001
17. Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management
of Metastatic Melanoma: Improved Survival in a National Cohort Following
the Approvals of Checkpoint Blockade Immunotherapies and Targeted
Therapies. Cancer Immunol Immunother (2018) 67(12):1833–44. doi:
10.1007/s00262-018-2241-xFrontiers in Oncology | www.frontiersin.org 918. Gutiérrez-González E, López-Abente G, Aragonés N, PollánM, Pastor-Barriuso R,
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epidemiológiája (Klinikai tapasztalatok az Országos Onkológiai Intézetben)
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